Phaseline

Companies › iCell Gene Therapeutics

iCell Gene Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Hematology, Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ICG318
BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain
TNFRSF17, CD19, BCMAPhase 2Systemic Lupus Erythematosus (SLE); Inflammatory MyopathyDec 2027
BCMA-CD19 cCAR T cells
Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c
BCMA, CD19Phase 1Multiple Myeloma in Relapse; Refractory Immune CytopeniaApr 2027
Anti-CD33-CLL1 CAR-T cells (ICG415)
Autologous CAR-T cells targeting CD33 and CLL1
–Phase 1Acute Myeloid Leukemia (AML)Jul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04162353BCMA-CD19 cCAR T cellsPhase 1Multiple Myeloma in RelapseOncologyJul 2026
NCT06787989BCMA-CD19 cCAR T cellsPhase 1Refractory Immune CytopeniaHematologyApr 2027
NCT07715136ICG318Phase 1Inflammatory MyopathyImmunologyDec 2027
NCT07668557Anti-CD33-CLL1 CAR-T cells (ICG415)Phase 1Acute Myeloid Leukemia (AML)OncologyJul 2028
NCT07328581ICG318Phase 2Systemic Lupus Erythematosus (SLE)ImmunologyDec 2028

Targets

BCMA (2) CD19 (2) TNFRSF17 (1)

Companies with the same targets

Chongqing Precision Biotech Gilead Sciences Bristol-Myers Squibb Johnson & Johnson (Janssen) AstraZeneca Gracell Biotechnologies (Shanghai) Roche Kali Therapeutics Allogene Therapeutics Miltenyi Biomedicine

Companies built like this

Juventas Cell Therapy Beijing Yongtai Ruike Biotechnology Company Hrain Biotechnology Jiangsu Topcel-KH Pharmaceutical Hebei Senlang Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.